Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC.JUNS · Entity 8326 | Director | June 26, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JUPITER NEUROSCIENCES, INC.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2036-06-29 | Direct | 536,428 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 536,428 · Balance 536,428 F1: Represents a grant of 536,428 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. Of this amount, 90,000 options were granted in connection with the Reporting Person's appointment to the Board of Directors and 446,428 options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning September 2, 2026, subject to the Reporting Person's continued service as a director through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of 536,428 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. Of this amount, 90,000 options were granted in connection with the Reporting Person's appointment to the Board of Directors and 446,428 options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning September 2, 2026, subject to the Reporting Person's continued service as a director through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jul 1, 2026 20:02 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | GrantStock Option (right to buy) · Derivative | 536,428 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-26-031539 · ownership.xml · derivative · entry 1 Philipson Tomas Jan · CIK 0002142237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,428 Underlying: Common Stock · 536,428 shares Expires 2036-06-29 F1 · derivative.exercise_date: Represents a grant of 536,428 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. Of this amount, 90,000 options were granted in connection with the Reporting Person's appointment to the Board of Directors and 446,428 options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning September 2, 2026, subject to the Reporting Person's continued service as a director through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.